Printer Friendly
The Free Library
19,595,263 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Antigenics Prices $62 Million Public Offering of Common Stock.


Business Editors & Health/Medical Writers

BIOWIRE2K

NEW YORK--(BUSINESS WIRE)--Jan. 23, 2003

Antigenics Inc. (NASDAQ NASDAQ
 in full National Association of Securities Dealers Automated Quotations

U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on
: AGEN) announced today that it has agreed to sell 6.25 million shares of its common stock.

The total public offering price is approximately $62 million. Of the 6.25 million shares, 3.45 million shares are being sold to an underwriting syndicate Underwriting syndicate

A group of investment banks that work together to sell new security offerings to investors. The underwriting syndicate is led by the lead underwriter. See also: Lead underwriter.


underwriting syndicate

See syndicate.
 managed by UBS UBS Union Bank of Switzerland
UBS United Bible Societies
UBS United Blood Services
UBS United Buying Service
UBS Used Bookstore
UBS University Business Services
UBS Universal Building Society (UK)
UBS Ulaanbaatar Broadcasting System
 Warburg LLC (Logical Link Control) See "LANs" under data link protocol.

LLC - Logical Link Control
, Needham & Company, Inc., Morgan Keegan & Company, Inc. and Ryan Beck & Co., and 2.8 million shares are being sold directly by the company to an existing shareholder. In addition, the underwriters have an option to purchase up to 517,500 shares to cover over-allotments. The offering is being made under effective registration statements. The sales are subject to closing conditions.

UBS Warburg LLC is acting as the lead underwriter Lead underwriter

The head of a syndicate of financial firms that are sponsoring an initial public offering of securities or a secondary offering of securities. Could also apply to bond issues.
 for the underwritten component.

Antigenics develops products to treat cancers, infectious diseases and autoimmune disorders.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities. This offering of shares of common stock may be made only by means of a prospectus, a copy of which will be available from UBS Warburg LLC, 229 Park Avenue, New York, New York 10171.
COPYRIGHT 2003 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Jan 23, 2003
Words:205
Previous Article:MB Financial, Inc. Reports Record Fourth Quarter and Annual Earnings for 2002.
Next Article:Aether Partners with TransCommunications and Mobilacomm Eagle to Launch New Asset Monitoring System, GeoLogic; Leading Truckload Carrier U.S. Xpress...
Topics:



Related Articles
VALENCIA BANK IN MERGER UNIONBANCAL DEAL TO ADD LOCAL CLOUT.
Antigenics Announces Proposed Equity Sale.
Antigenics Reports Fourth Quarter and Year-End 2002 Results.
Antigenics Announces Placement of Convertible Preferred Stock.
Antigenics Reports Third Quarter 2003 Financial Results and Recent Highlights.
Antigenics Announces Proposed Equity Sale.
Antigenics Prices $52.5 Million Public Offering of Common Stock.
Antigenics Reports Fourth Quarter and Year-End 2003 Financial Results and Highlights.
Antigenics Reports First Quarter 2004 Financial Results and Recent Highlights.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles